



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known			
		Application Number	10/802,497-Conf. #3969		
		Filing Date	March 16, 2004		
		First Named Inventor	Matthew During		
		Art Unit	1614 1632		
		Examiner Name	Not Yet Assigned Anne-Marie Falk, Ph.D.		
Sheet	2 1	of	2	Attorney Docket Number	102182-0036

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/AMF/	AA	5,187,162	02/16/1993	Marangos et al.	
/AMF/	AB	5,681,744	10/28/1997	Greenstein	
/AMF/	AC	6,682,906	01/27/2004	Tobin et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
/AMF/	BA	WO 95/25805	09/28/1995	PCT		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
/AMF/	CA	Bu <i>et al.</i> , "Two Human Glutamate Decarboxylases, 65-kDa GAD and 67-kDa GAD, Are Each Encoded by a Single Gene," <i>Proc. Natl. Acad. Sci. USA</i> , vol. 89, 2115-2119 (March 1992);			
	CB	Cao <i>et al.</i> , "High-Titer, Wild-Type Free Recombinant Adeno-Associated Virus Vector Production Using Intron-Containing Helper Plasmids," <i>Journal of Virology</i> , vol. 74, no. 24, 11456-11463 (December 2000);			
	CC	Celada <i>et al.</i> , "Gabaergic Control of Rat Substantia Nigra Dopaminergic Neurons: Role of Globus Pallidus and Substantia Nigra Pars Reticulata," <i>Neuroscience</i> , vol. 89, no. 3, 813-825 (1999);			
	CD	During <i>et al.</i> , "Peroral Gene Therapy of Lactose Intolerance Using an Adeno-Associated Virus Vector," <i>Nature Medicine</i> , vol 4, no. 10 (October 1998);			
	CE	Kotin, Robert M., "Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy," <i>Human Gene Therapy</i> , vol. 5, 793-801 (1994);			
	CF	Linderfors, Nils, "Dopaminergic Regulation of Glutamic Acid Decarboxylase mRNA Expression and GABA Release in the Striatum: A Review," <i>Prog. Neuro-Psychopharmacol & Biol. Psychiatry</i> , vol. 17, 887-903 (1993);			
	CG	Martin <i>et al.</i> , "Are GAD ₆₅ and GAD ₆₇ Associated with Specific Pools of GABA in Brain?" <i>Perspectives on Developmental Neurobiology</i> , vol. 5, 119-129 (1998);			
	CH	Miller <i>et al.</i> , "The Central Medial Nucleus: Thalamic Site of Seizure Regulation," <i>Brain Research</i> , vol. 508, 297-300 (1990);			
	CI	Schenk <i>et al.</i> , "Immunization with Amyloid- β Attenuates Alzheimer-Disease-Like Pathology in the PDAPP Mouse," <i>Nature</i> , vol. 400, 173-177 (July 1999);			
	CJ	Veliskova <i>et al.</i> , "Subthalamic Nucleus: A New Anticonvulsant Site in the Brain," <i>Neuroreport</i> , vol. 7, no. 11, 1786-1788 (1996); and			
/AMF/	CK	Xu <i>et al.</i> , "Is the Anticonvulsant Effect of Substantia Nigra Infusion of Gama-Vinyl-GABA (GVG) Mediated by the GABA _A Receptor in Rat Pups?" <i>Developmental Brain Research</i> , vol. 59, 17-21 (1991).			

Examiner Signature	/Anne Marie Falk/	Date Considered	06/21/2007
-----------------------	-------------------	--------------------	------------



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known			
		Application Number	10/802,497-Conf. #3969		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	March 16, 2004		
		First Named Inventor	Matthew During		
		Art Unit	4644 1632		
		Examiner Name	Not Yet Assigned Anne-Marie Falk, Ph.D.		
Sheet	2	of	2	Attorney Docket Number	102182-0036

/AMF/	CL	Robert, JJ et al. "Adenovirus-Mediated Transfer of a Functional GAD Gene Into Nerve Cells: Potential For The Treatment of neurological Diseases" Gene Therapy, Vol. 4, No. 11, pgs. 1237-1245 (1997)	
/AMF/	CM	Mi, Jie et al. "Recombinant Aden-Associated Virus (AAV) Drives Constitutive Production of Glutamate Decarboxylase In Neural Cell Lines" Journal of Neuroscience Research, Vol. 57, pgs. 137-148 (1999);	
/AMF/	CN	New, Kent et al. "Novel Synthesis and Release of GABA In Cerebellar Granule Cell Cultures After Infection With Defective Herpes Simplex Virus Vectors Expressing Glutamic Acid Decarboxylase" Molecular Brain Research, Vol., pgs. 121-135 (1998);	
/AMF/	CO	Navarro, V. et al. "Efficient Gene Transfer and Long-Term Expression In Neurons Using A Recombinant Adenovirus With A neuron-Specific Promoter" Gene Therapy, Vol. 6, pgs. 1884-1892 (1999)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Anne Marie Falk/	Date Considered	06/21/2007
-----------------------	-------------------	--------------------	------------